Genocea Biosciences announced today the presentation of new data
supporting its novel approach to developing a first-in-class, protein
subunit therapeutic vaccine for Herpes Simplex Virus type 2 (HSV-2). The
data, to be presented this week at the 37th annual International
Herpesvirus Workshop (IHW) in Calgary, Alberta, highlight antigens
identified through Genocea's unique technology platform that stimulate T
cell immune responses to HSV-2. A candidate vaccine consisting of these
antigens reduced viral shedding and clinical disease when tested in a
preclinical model of HSV-2 infection.
"We are highly encouraged by these data, which mark the first time a
protein subunit therapeutic vaccine has been shown to affect disease and
viral shedding significantly in this model," said Jessica Flechtner,
Ph.D., Vice President, Research, Genocea Biosciences. "As we advance
toward the clinic, these data give us great confidence in our lead
vaccine candidate, and suggest that we have identified full protein
antigens that stimulate a balanced and effective B and T cell immune
response."